References
- Angel P. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 1987; 49: 729–739
- Arch R. Participation in normal immune responses of a splice variant of CD44 that encodes a metastasis-inducing domain. Science 1992; 257: 682–685
- Bartolazzi A. Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J. Cell Biol. 1996; 132: 1199–1208
- Bennett K. L. CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J. Cell Biol. 1995a; 128: 687–698
- Bennett K. L. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J. Cell Biol. 1995b; 131: 1623–1633
- Crossley P. H. Role for FGF8 in the induction, initiation, and maintenance of chick limb development. Cell 1996; 84: 127–136
- Culty M. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J. Cell Biol. 1992; 116: 1055–1062
- DeGrendele H. C. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278: 672–675
- Günthert U. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13–24
- Herrlich P. CD44 and splice variants of CD44 in normal differentiation and tumor progression. “Cell adhesion molecules”, M. E. Hemler, E. Mihich. Plenum Press, New York and London 1993; 265–288
- Hofmann M. A link between RAS and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 1993; 53: 1516–1521
- Jackson D. G. Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J. Biol. Chem. 1992; 267: 4732–4739
- Jackson D. G. Proteoglycan forms on the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J. Cell Biol. 1995; 128: 673–685
- Jalkanen S. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85–95 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J. Cell Biol. 1987; 105: 983–990
- Jalkanen S. Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J. Immunol. 1988; 141: 1615–1623
- Katoh S. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J. Exp. Med. 1995; 182: 419–429
- Kaufmann M. CD44 variant exon epitopes in primary breast cancer and length of survival. The Lancet 1995; 345: 615–619
- Kaya G. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev. 1997; 11: 996–1007
- König H. Coupling of signal transduction to alternative pre-m RNA splicing by a composite splice regulator. EMBO J. 1998, in press
- Koopman G. Activated human lymphocytes and aggressive Non-Hodgkin lymphomas express a homologue of the rat metastasis-associated variant of CD44. J. Exp. Med. 1993; 177: 897–904
- Lamb R. F. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol. Cell Biol. 1997; 17: 963–976
- Lee W. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 1987; 49: 741–752
- Lesley J. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J. Exp. Med. 1995; 182: 431–437
- Lokeshwar V. B., Bourguignon. Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. J. Biol. Chem. 1991; 266: 17983–17989
- Lokeshwar V. B. Ankyrin-binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function. J. Cell Biol. 1994; 126: 1099–1109
- Mulder J.-W.R. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. The Lancet 1994; 344: 1470–1472
- Naor D. CD44: Structure, function and association with the malignant process. Adv. Cancer Res. 1997; 71: 241–319
- Niswander L., Martin G. R. Fgf-4 expression during gastrulation, myogenesis, limb and tooth development in the mouse. Development 1992; 114: 755–768
- Niswander L. FGF-4 replaces the apical ectodermal ridge and directs outgrowth and patterning of the limb. Cell 1993; 75: 579–587
- Peach R. J. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J. Cell Biol. 1993; 122: 257–264
- Rudy W. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res. 1993; 53: 1262–1268
- Saunders J. W., Jr. The proximal-distal sequence of origin of the parts of the chick limb and the role of the ectoderm. J. Exp. Zool. 1948; 108: 363–404
- Schmits R. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 1997; 90: 2217–2233
- Screaton G. R. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA 1992; 89: 12160–12164
- Sherman L. A splice variant of CD44 expressed in the apical ectodermal ridge presents FGFs to limb mesenchyme and is required for limb outgrowth. Genes Dev. 1998, in press
- Sleeman J. Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. J. Cell Biol. 1996a; 135: 1139–1150
- Sleeman J. P. Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Cancer Res. 1996b; 56: 3134–3141
- Sleeman J. Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44. J. Biol. Chem. 1997; 272: 31837–31841
- Sleeman J. CD44 variant exon v5 encodes a tyrosine which is sulphated. Eur. J. Biochem. 1998, in press
- Stauder R. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995; 85: 2885–2899
- Sy M.-S. Distinct effects of two CD44 isoforms on tumor growth in vivo. J. Exp. Med. 1991; 174: 859–866
- Sy M.-S. Inhibition of tumor growth in vino with a soluble CD44-immunoglobulin fusion protein. J. Exp. Med. 1992; 176: 623–627
- Taber T. E.I. Signalling through CD44 is mediated through tyrosine kinases: association with p56lck in T lymphocytes. J. Biol. Chem. 1996; 271: 2863–2867
- Tanaka Y. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lb. Nature 1993; 361: 79–82
- Tölg C. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res. 1993; 21: 1225–1229
- Wainwright D. A splice variant of CD44 expressed in the rat apical ectodermal ridge contributes to limb out-growth. Ann. NY Acad. Sci. 1996; 785: 345–349
- Weiss J. M. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J. Cell Biol. 1997; 137: 1137–1147
- Wirth K. Expression of CD44 isoforms carrying metastasis-associated sequences in newborn and adult rats. Eur. J. Cancer 1993; 29A: 1177–1183
- Yang B. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J. 1994; 13: 286–296
- Zahalka M. A. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J. Immunol. 1995; 154: 5345–5355
- Zheng J. Keratinocyte growth factor is a bifunctional regulator of HPV16 DNA-immortalized cervical epithelial cells. J. Cell Biol. 1995; 129: 843–851
- Zhou D. F.H. Molecular cloning and expression of Pgp-1 – The mouse homolog of the human H-CAM (Hermes) lymphocyte homing receptor. J. Immunol. 1989; 143: 3390–3395